# CD52

## Overview
CD52 is a gene that encodes a small glycoprotein, prominently expressed on the surface of various immune cells, including lymphocytes, monocytes, and macrophages, as well as in the male reproductive tract (Rashidi2017CD52; Bandala-Sanchez2018CD52). The CD52 protein, also known as the CAMPATH-1 antigen, is characterized by its glycosylphosphatidylinositol (GPI) anchor, which facilitates its attachment to the cell membrane (Xia1993Structure). Functionally, CD52 plays a critical role in modulating immune responses, primarily through interactions with the Siglec-10 receptor on T cells, thereby inhibiting T cell activation and proliferation (Rashidi2017CD52; Zhao2017The). Additionally, soluble CD52 acts as a negative regulator of inflammatory signaling pathways, contributing to immune homeostasis (Rashidi2017CD52). Clinically, alterations in CD52 expression are implicated in various diseases, including systemic lupus erythematosus and chronic lymphocytic leukemia, where it serves as a potential biomarker and therapeutic target (Bhamidipati2021CD52; Albitar2004Free).

## Structure
The CD52 protein, also known as the CAMPATH-1 antigen, is a small glycoprotein anchored to the cell membrane via a glycosylphosphatidylinositol (GPI) anchor. The primary structure of CD52 consists of a short peptide backbone with 12 amino acids, specifically the sequence GQNDTSQTSSPS, with an N-glycosylation site at Asn-3 and a GPI anchor attachment at Ser-12 (Xia1993Structure; Schröter1999Malespecific). The mature protein is predicted to be remarkably short, comprising no more than 18 residues and possibly as few as 12, depending on the GPI linkage site (Xia1991Characterization).

CD52 undergoes post-translational modifications, including N-linked glycosylation, which contributes significantly to its molecular mass and structure. The glycan structures are complex and heterogeneous, with the male genital tract form of CD52 displaying distinct N-linked glycans compared to the lymphocyte form (Schröter1999Malespecific; Kirchhoff2000New). The GPI anchor is a significant component of the protein, with structural variations such as inositol acylation contributing to its properties (Schröter1999Malespecific).

Due to its small size, CD52 lacks extensive secondary, tertiary, or quaternary structures, and its function is largely attributed to its glycosylation and membrane anchoring (Xia1991Characterization). The protein is expressed on lymphocytes and monocytes, as well as in the male genital tract, where it is incorporated into the sperm membrane (Schröter1999Malespecific).

## Function
The CD52 gene encodes a small glycoprotein that is highly expressed on the surface of various immune cells, including lymphocytes, monocytes, macrophages, and dendritic cells, as well as in the male reproductive tract (Rashidi2017CD52; Zhao2017The; Bandala-Sanchez2018CD52). CD52 plays a crucial role in modulating immune responses and maintaining immune homeostasis. It is involved in the suppression of T-cell activation by binding to the Siglec-10 receptor on activated T cells, which inhibits T cell proliferation and activation (Rashidi2017CD52; Zhao2017The). This interaction requires the damage-associated molecular pattern protein, high-mobility group box 1 (HMGB1), which facilitates the binding of CD52 to Siglec-10 (Bandala-Sanchez2018CD52).

Soluble CD52, released from the cell surface by phospholipase C, acts as an extracellular negative regulator of pattern recognition receptor signaling, inhibiting NF-κB and ERK pathways, which reduces the production of inflammatory cytokines (Rashidi2017CD52). At higher concentrations, soluble CD52 can induce apoptotic cell death by depleting the pro-survival protein MCL-1 and activating BH3-only proteins BAX and BAK (Rashidi2017CD52). These functions suggest that CD52 is integral to controlling inflammation and preventing excessive immune responses, thereby contributing to immune homeostasis in healthy human cells (Rashidi2017CD52).

## Clinical Significance
Alterations in CD52 expression and its interactions have significant clinical implications in various diseases. In systemic lupus erythematosus (SLE), CD52 expression is elevated on B cells, particularly in non-switched memory B cells, which are depleted in SLE patients. This upregulation correlates with increased disease activity and inflammation, as indicated by elevated soluble CD52 levels in plasma, which are associated with clinical parameters such as complement consumption and C-reactive protein levels (Bhamidipati2021CD52).

In chronic lymphocytic leukemia (CLL), patients exhibit significantly higher levels of soluble CD52 compared to healthy individuals. This elevation is not due to cell degradation but is likely a result of shedding from cells, suggesting its potential as a tumor marker and its interaction with therapeutic antibodies like alemtuzumab (Albitar2004Free).

In advanced systemic mastocytosis (SM), CD52 is expressed on neoplastic mast cells, making it a potential therapeutic target. The CD52-targeting antibody alemtuzumab has shown efficacy in inducing cell death in CD52-positive neoplastic mast cells, highlighting its role in treating aggressive hematopoietic neoplasms (Hoermann2014CD52).

In FLT3-ITD-mutated myeloid leukemia, CD52 expression is upregulated, and targeting it with alemtuzumab has demonstrated potential therapeutic benefits, including antibody-dependent cellular cytotoxicity and tumor growth suppression (Karnan2021CD52).

## Interactions
CD52 is a glycoprotein that participates in several interactions with other proteins, primarily through its soluble form. One key interaction is with the Siglec-10 receptor on T cells. Soluble CD52 binds to Siglec-10, leading to the suppression of T cell activation by impairing the phosphorylation of T-cell receptor-associated kinases Lck and Zap-70. This interaction involves the recruitment of SHP phosphatases, which are crucial for the inhibitory signaling pathway (Bandala-Sanchez2018CD52; Toh2013Immune).

CD52 also interacts with the proinflammatory protein HMGB1. The glycan structure of CD52 binds to the proinflammatory B box of HMGB1, facilitating its engagement with Siglec-10. This interaction is essential for the immunosuppressive function of CD52, as it helps maintain immune homeostasis by suppressing T cell function (Shathili2019Specific; Bandala-Sanchez2018CD52).

In addition to its role in T cell regulation, CD52 influences B cell function. Soluble CD52 inhibits B cell receptor (BCR) signaling by reducing calcium flux responses and phosphorylation of signaling molecules such as phospho-BTK, phospho-SYK, and phospho-PLC-g2. This effect is partially mediated through its interaction with Siglec-10 (Bhamidipati2021CD52).


## References


[1. (Schröter1999Malespecific) Sabine Schröter, Petra Derr, Harald S. Conradt, Manfred Nimtz, Geoffrey Hale, and Christiane Kirchhoff. Male-specific modification of human cd52. Journal of Biological Chemistry, 274(42):29862–29873, October 1999. URL: http://dx.doi.org/10.1074/jbc.274.42.29862, doi:10.1074/jbc.274.42.29862. This article has 101 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.274.42.29862)

[2. (Karnan2021CD52) Sivasundaram Karnan, Ichiro Hanamura, Akinobu Ota, Souichi Takasugi, Ayano Nakamura, Miyuki Takahashi, Kaori Uchino, Satsuki Murakami, Md Wahiduzzaman, Lam Quang Vu, Md Lutfur Rahman, Muhammad Nazmul Hasan, Toshinori Hyodo, Hiroyuki Konishi, Shinobu Tsuzuki, Kazuhiro Yoshikawa, Susumu Suzuki, Ryuzo Ueda, Masayuki Ejiri, Yoshitaka Hosokawa, and Akiyoshi Takami. Cd52 is a novel target for the treatment of flt3-itd-mutated myeloid leukemia. Cell Death Discovery, May 2021. URL: http://dx.doi.org/10.1038/s41420-021-00446-8, doi:10.1038/s41420-021-00446-8. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41420-021-00446-8)

[3. (Xia1991Characterization) Meng‐Qi Xia, Masahide Tone, Len Packman, Geoff Hale, and Herman Waldmann. Characterization of the campath‐1 (cdw52) antigen: biochemical analysis and cdna cloning reveal an unusually small peptide backbone. European Journal of Immunology, 21(7):1677–1684, July 1991. URL: http://dx.doi.org/10.1002/eji.1830210714, doi:10.1002/eji.1830210714. This article has 135 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/eji.1830210714)

[4. (Rashidi2017CD52) Maryam Rashidi, Esther Bandala-Sanchez, Kate E Lawlor, Yuxia Zhang, Alana M Neale, Swarna L Vijayaraj, Robert O’Donoghue, John M Wentworth, Timothy E Adams, James E Vince, and Leonard C Harrison. Cd52 inhibits toll-like receptor activation of nf-κb and triggers apoptosis to suppress inflammation. Cell Death &amp; Differentiation, 25(2):392–405, December 2017. URL: http://dx.doi.org/10.1038/cdd.2017.173, doi:10.1038/cdd.2017.173. This article has 42 citations.](https://doi.org/10.1038/cdd.2017.173)

[5. (Zhao2017The) Yang Zhao, Huiting Su, Xiaofei Shen, Junfeng Du, Xiaodong Zhang, and Yong Zhao. The immunological function of cd52 and its targeting in organ transplantation. Inflammation Research, 66(7):571–578, March 2017. URL: http://dx.doi.org/10.1007/s00011-017-1032-8, doi:10.1007/s00011-017-1032-8. This article has 79 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00011-017-1032-8)

[6. (Bandala-Sanchez2018CD52) Esther Bandala-Sanchez, Naiara G. Bediaga, Ethan D. Goddard-Borger, Katrina Ngui, Gaetano Naselli, Natalie L. Stone, Alana M. Neale, Lesley A. Pearce, Ahmad Wardak, Peter Czabotar, Thomas Haselhorst, Andrea Maggioni, Lauren A. Hartley-Tassell, Timothy E. Adams, and Leonard C. Harrison. Cd52 glycan binds the proinflammatory b box of hmgb1 to engage the siglec-10 receptor and suppress human t cell function. Proceedings of the National Academy of Sciences, 115(30):7783–7788, July 2018. URL: http://dx.doi.org/10.1073/pnas.1722056115, doi:10.1073/pnas.1722056115. This article has 62 citations.](https://doi.org/10.1073/pnas.1722056115)

[7. (Albitar2004Free) Maher Albitar, Kim‐Anh Do, Marcella M. Johnson, Francis J. Giles, Iman Jilani, Susan O’Brien, Jorge Cortes, Deborah Thomas, Laura Z. Rassenti, Thomas J. Kipps, Hagop M. Kantarjian, and Michael Keating. Free circulating soluble cd52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti‐cd52 antibodies. Cancer, 101(5):999–1008, August 2004. URL: http://dx.doi.org/10.1002/cncr.20477, doi:10.1002/cncr.20477. This article has 69 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/cncr.20477)

[8. (Shathili2019Specific) Abdulrahman M. Shathili, Esther Bandala-Sanchez, Alan John, Ethan D. Goddard-Borger, Morten Thaysen-Andersen, Arun V. Everest-Dass, Timothy E. Adams, Leonard C. Harrison, and Nicolle H. Packer. Specific sialoforms required for the immune suppressive activity of human soluble cd52. Frontiers in Immunology, August 2019. URL: http://dx.doi.org/10.3389/fimmu.2019.01967, doi:10.3389/fimmu.2019.01967. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2019.01967)

[9. (Toh2013Immune) Ban-Hock Toh, Tin Kyaw, Peter Tipping, and Alex Bobik. Immune regulation by cd52-expressing cd4 t cells. Cellular &amp; Molecular Immunology, 10(5):379–382, August 2013. URL: http://dx.doi.org/10.1038/cmi.2013.35, doi:10.1038/cmi.2013.35. This article has 23 citations.](https://doi.org/10.1038/cmi.2013.35)

[10. (Kirchhoff2000New) Christiane Kirchhoff and Sabine Schröter. New insights into the origin, structure and role of cd52: a major component of the mammalian sperm glycocalyx. Cells Tissues Organs, 168(1–2):93–104, November 2000. URL: http://dx.doi.org/10.1159/000016810, doi:10.1159/000016810. This article has 57 citations and is from a peer-reviewed journal.](https://doi.org/10.1159/000016810)

[11. (Xia1993Structure) M Q Xia, G Hale, M R Lifely, M A J Ferguson, D Campbell, L Packman, and H Waldmann. Structure of the campath-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochemical Journal, 293(3):633–640, August 1993. URL: http://dx.doi.org/10.1042/bj2930633, doi:10.1042/bj2930633. This article has 154 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1042/bj2930633)

[12. (Bhamidipati2021CD52) Kartik Bhamidipati, John L. Silberstein, Yashaar Chaichian, Matthew C. Baker, Tobias V. Lanz, Amin Zia, Yusuf S. Rasheed, Jennifer R. Cochran, and William H. Robinson. Cd52 is elevated on b cells of sle patients and regulates b cell function. Frontiers in Immunology, February 2021. URL: http://dx.doi.org/10.3389/fimmu.2020.626820, doi:10.3389/fimmu.2020.626820. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2020.626820)

[13. (Hoermann2014CD52) Gregor Hoermann, Katharina Blatt, Georg Greiner, Eva Maria Putz, Angelika Berger, Harald Herrmann, Sabine Cerny‐Reiterer, Karoline V. Gleixner, Christoph Walz, Konrad Hoetzenecker, Leonhard Müllauer, Andreas Reiter, Karl Sotlar, Veronika Sexl, Peter Valent, and Matthias Mayerhofer. Cd52 is a molecular target in advanced systemic mastocytosis. The FASEB Journal, 28(8):3540–3551, April 2014. URL: http://dx.doi.org/10.1096/fj.14-250894, doi:10.1096/fj.14-250894. This article has 20 citations.](https://doi.org/10.1096/fj.14-250894)